Homepage

Sandoz HACk - Healthcare Access Challenge

Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
Read More
our-mission-and-purpose

Our Mission and Purpose

We are a global leader in generic and biosimilar pharmaceuticals, committed to driving access to medicine
Read More

Explore Novartis

About Us
Who We Are
Our Work
What We Do
About Us
Corporate Responsibility
Careers
Job Search

Recent Updates

Biosimilars in the US: Time to stop the towels blocking the deckchairs
Featured / Aug 28

Biosimilars in the US: Time to stop the towels blocking the deckchairs

Richard Saynor via LinkedIn

Learn More
View All
Media Release / Sep 03

Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine

Read More
Featured News / Aug 28

Biosimilars in the US: Time to stop the towels blocking the deckchairs

Richard Saynor via LinkedIn
Read More
Media Release / Aug 09

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case

Read More
Media Release / Jul 22

Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis

Read More
View All
A #biosimilar is a follow-on medicine of existing #biologic when the patent has expired. Who benefits from #biosimilaradoption? 13 hours 35 min ago

Our Work

At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine.

Learn More